Microsphere-Based ANCA Detection via Flow Cytometry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and quantifying anti-neutrophil cytoplasmic antibodies (ANCA) in bodily fluids are inefficient, lacking precise quantitation and requiring labor-intensive visual microscopy with high variability, which hinders effective monitoring of autoimmune diseases and immunosuppressive therapy.
Innovation Solution
A microsphere-based flow cytometric assay is developed, where microspheres are coupled with ANCA-targeting antigens from polymorphonuclear neutrophils, allowing for the detection and quantification of ANCA in bodily fluids through flow cytometry, enabling multiplex analysis and automated interpretation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If indirect immunofluorescence with visual microscopy is used to detect ANCA, then the method is simple to perform, but it lacks precise quantitation and has high variability
Solution Approach 1:
The patent replaces the mechanical visual microscopy system with a flow cytometry-based detection system. Microspheres coupled with ANCA-targeting antigens are used as substrates, and flow cytometry provides automated, quantitative measurement of ANCA levels, eliminating the subjectivity and variability of visual assessment while maintaining operational simplicity through standardized protocols
Solution Approach 2:
The patent changes the measurement parameter from qualitative/semi-quantitative visual fluorescence intensity to quantitative flow cytometry parameters (fluorescence intensity per microsphere, particle count). This parameter transformation enables precise quantitation of ANCA levels, allowing for accurate monitoring of disease activity and therapy response
2Productivity
If visual microscopy is used for ANCA detection, then the equipment requirement is low, but it requires labor-intensive manual analysis with high variability
Solution Approach 1:
The patent replaces manual visual microscopy with automated flow cytometry analysis. The flow cytometer automatically detects, counts, and quantifies fluorescent microspheres bound with ANCA, eliminating labor-intensive manual image analysis while increasing detection throughput through high-speed automated processing of multiple samples
Solution Approach 2:
The flow cytometry system performs self-service automated analysis, where the instrument independently completes sample processing, data acquisition, and quantification without requiring manual intervention. The system automatically generates quantitative results, reducing operator workload and eliminating inter-observer variability
3Adaptability or versatility
If conventional ANCA detection methods are used, then the methodology is established, but it cannot simultaneously measure multiple autoantibodies
Solution Approach 1:
The patent creates a universal microsphere-based platform that can detect multiple types of autoantibodies simultaneously. By coupling different antigens (e.g., PR3, MPO, elastase, cathepsin G) to microspheres, the system can perform multiplex detection of various ANCA specificities in a single assay, enabling comprehensive autoimmune disease characterization
Solution Approach 2:
The patent segments the detection of different autoantibodies by using distinct microsphere populations, each coupled with specific antigens. This segmentation allows simultaneous measurement of multiple autoantibody types (anti-PR3, anti-MPO, anti-elastase, etc.) through flow cytometry, with each microsphere type providing specific information about particular autoantibody targets
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides improved precision, accuracy, and reduced time for ANCA detection and quantification, overcoming limitations of existing techniques by enabling objective, automated analysis and simultaneous measurement of multiple autoantibodies, facilitating better disease monitoring and therapy adaptation.
Implementation Method 1
contacting a defined sample of serum or plasma suspected of containing human auto-antibodies under antibody-binding conditions with a defined number or amount of microspheres that have been associated or coupled with one or more ANCA-targeting antigens
Implementation Method 2
subjecting the sample to flow-cytometry to determine the number or fraction of microspheres having bound auto-antibodies
Data Source
AI summary
A method for detecting and quantifying anti-neutrophil-cytoplasmic antibodies (ANCA) in a sample of bodily fluid from a patient suspected of suffering from an autoimmune disease, including the steps of contacting human polymorphonuclear neutrophils able to release extracellular traps (NETs) with microspheres to produce NET-coated microspheres, contacting the NET-coated microspheres with the sample of bodily fluid, and labeling and subsequent analyzing of anti-neutrophil-cytoplasmic antibodies by flow cytometric methods.